- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05401942
Real-time Tele-monitoring Versus Routine Monitoring of Breast Cancer Patients Receiving Adjuvant Systemic Therapy
Real-time Tele-monitoring Versus Routine Monitoring of Breast Cancer Patients Receiving Adjuvant Systemic Therapy.
Patients with breast cancer receiving systemic therapy have a variety of symptoms.
In cancer patients receiving chemotherapy and targeted therapy, it is common to report symptoms to physicians before each cycle of systemic therapy and planning maintenance and treatment applications accordingly. Nowadays tele-monitoring of patient reported outcomes using mobile applications is used widely.
These applications provide many advantages to the patient, physicians, and health care system because patients report the symptoms experienced and helps contribute to the quick management of the symptoms and improve the adherence to treatment, decrease the frequency of dose delays and dose reduction of their treatment.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In Egypt, breast cancer is the most frequent malignancy among Egyptian women, accounting for 38.8% of cancers in this population, with the expected number of breast cancer cases nearly 22, 700 in 2020 and forecasted to be approximately 46, 000 in 2050.It is found that the breast cancer mortality rate is around 11%, being the second cause of cancer-related mortality after hepatocellular carcinoma.
Systemic therapy including chemotherapy and antiHER2 drugs are frequently utilized in the adjuvant setting in the treatment of breast cancer as Anthracycline-based chemotherapy (AC, FEC, FAC Protocols containing Doxorubicin, Epirubicin, fluorouracil and cyclophosphamide), which may lead to cardiac side effects, taxanes (Paclitaxel and Docetaxel) which may lead to GIT Problems and peripheral neuropathy. The addition of trastuzumab to a sequential anthracycline/cyclophosphamide-taxane regimen was linked to a 3% risk of cardiac toxicity, whereas trastuzumab in conjunction with non-anthracycline regimens (e.g. carboplatin/docetaxel) was linked to lower rates of cardiac toxicity.
These drugs may result in a variety of symptoms to develop, it is critical to measure, prevent and control them. Patient-reported outcomes (PROs) are becoming more popular as a way to quantify symptoms and health-related quality of life in cancer care. PROs are useful to capture the patient's perspective on their care and treatment, and they are intended to supplement traditional clinical outcomes and toxicity reported by physicians such as survival and toxicity assessment.
Tele-monitoring is crucial in patients' follow-up as it will improve patients' adherence to treatment, decrease the frequency in dose reduction and dose delay. This will be accomplished by using tele-monitoring in reporting and managing patient reported outcomes from chemotherapy using PRO- CTCAE Checklist, version 1 to assess the grade and severity of symptoms reported by patients throughout the course of adjuvant chemotherapy with early management compared to the routine monitoring done in the regular clinic visits. In order to avoid the complications, symptoms should be diagnosed early and symptom referral for management should be advised and offered with evidence-based approaches. For this purpose, symptom reporting has recently been using mobile applications.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Stage I-III breast cancer under adjuvant intravenous chemotherapy with or without targeted therapy.
- Able to provide a written informed consent .
- Must have an internet access.
Exclusion Criteria:
- Presence of other malignancies whether in the past or simultaneously.
- Male cancer patients.
- Clinical diagnosis of Alzheimer's disease.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Routine monitoring
patients with breast cancer who will receive adjuvant treatment and will be followed up during treatment with routine visits.
|
|
Active Comparator: Tele-monitoring through mobile application
Patients with breast cancer who will receive adjuvant therapy and will be followed up during treatment through tele-monitoring with mobile application and CTCAE checklist for PRO.
|
Tele-monitoring of Patient reported outcomes
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison of frequency and severity of symptoms using real-time tele-monitoring versus routine symptom monitoring.
Time Frame: 2 years
|
To compare between grade of side effects of treatment between both arms through CTCAE checklist for patient reported outcomes.
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
● Comparison of adherence to treatment between both groups.
Time Frame: 3 years
|
to compare the tolerability for treatment between both arms through assessment of the percentage of dose delay in both groups.
|
3 years
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 261\2021
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer Female
-
Institut fuer FrauengesundheitNovartis Pharmaceuticals; AGO Breast Study Group e.V.RecruitingBreast Cancer | Breast Neoplasms | Advanced Breast Cancer | Breast Neoplasm Female | Breast Cancer Female | HER2-negative Breast Cancer | Hormone Receptor-positive Breast CancerGermany
-
H. Lee Moffitt Cancer Center and Research InstituteNovartisCompletedBreast Cancer | Breast Cancer - Female | Breast Cancer - MaleUnited States
-
University of Illinois at ChicagoRecruitingBreast Cancer Female | Breast Cancer InvasiveUnited States
-
Ahon Pharmaceutical Co., Ltd.RecruitingAdvanced Breast Cancer | Female Breast CancerChina
-
Ahon Pharmaceutical Co., Ltd.RecruitingAdvanced Breast Cancer | Female Breast CancerChina
-
Quanta MedicalLattice MedicalRecruitingBreast Reconstruction | Breast Cancer Female | Breast Cancer PreventGeorgia, France
-
Institut fuer FrauengesundheitEisai GmbHRecruitingAssessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer (AIRE)Breast Cancer Female | Breast Cancer Metastatic | Neoplasm, BreastGermany
-
Masaryk UniversityMasaryk Memorial Cancer InstituteRecruitingBreast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage IIICzechia
-
University of ChicagoRecruitingBreast Cancer | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage IIINigeria
-
Intuitive SurgicalRecruitingBreast Cancer | Breast Cancer Female | Breast | Breast Disease | Breast Cancer, Early-OnsetUnited States
Clinical Trials on Tele-monitoring through mobile application
-
King Khalid UniversityCompletedPhysical ActivitySaudi Arabia
-
National University Hospital, SingaporeCompletedPeriodontitis | Gingivitis | Plaque, DentalSingapore
-
Singapore General HospitalRootally AI PTE LTDNot yet recruiting
-
University Health Network, TorontoRecruitingBreast Cancer | Prostate CancerCanada
-
Children's Mercy Hospital Kansas CityCompletedCongenital Heart Disease | Mobile Health | Home MonitoringUnited States
-
Catholic University of the Sacred HeartCompleted
-
Erasme University HospitalCompleted
-
Erasme University HospitalCompleted
-
Yonsei UniversityCompleted
-
Butler HospitalNational Institute of Mental Health (NIMH); Brown UniversityNot yet recruitingSuicidal Ideation | Suicide, Attempted | Suicide | Suicide and Self-harmUnited States